document: of Qβ VLP-based therapeutics (TrQβ VLPs and TrQβ@b-3WJsiSCR MG) was evaluated to ensure their safety. Histopathologic examination revealed no obvious differences in the brain tissue sections of the saline, TrQβ VLPs, and TrQβ@b-3WJsiSCR MG-treated mice, indicating an absence of neurological toxicity during CED infusion of Qβ VLP-based therapeutics over a 5-day observation period (Figure S21). Our previous blood biochemical analyses showed that the Qβ VLP-based therapeutics would not cause both